Thursday 16 October, 2025
The pharmacokinetics of irinotecan (CPT-11) and four of its metabolites were studied in seventy cancer patients receiving short-term (about 1.5…
Read moreposter
A Population Pharmacokinetic-Pharmacodynamic Model for Ibandronate in Japanese Post-Menopausal Osteoporotic Women.
Thursday 16 October, 2025
Introduction & Objectives Ibandronate is a high potency amino-bisphosphonate in Phase III development for osteoporosis. A PK-PD model was developed…
Read moreA population pharmacokinetic model for doxorubucin in the presence of a novel P-gp Modulator, LY335979
Thursday 16 October, 2025
PURPOSE. Previous clinical investigations indicated that P-glycoprotein modulators dramatically decrease the systemic clearance of co-administered oncolytics. Potential impact of LY335979,…
Read moreImpact Of Model Misspecifications On Optimal Design And Hyperparameter Estimation In Population Pharmacokinetics
Thursday 16 October, 2025
Various methods for designing population experiments have been recently developed and rely on the optimization of an appropriate design criterion….
Read morePopulation Pharmacokinetics of a 24-hr Infusion of HMR1275 in Chronic Lymphocytic Leukemia Patients
Thursday 16 October, 2025
HMR1275 is a synthetic flavone inhibitor of cyclin-dependent kinases that induces apoptosis in vitro in human chronic lymphocytic leukemia (CLL)…
Read moreIndirect Pharmacodynamic Model With Two Different Markers Of Two Oral Anticoagulants In Patients
Thursday 16 October, 2025
Background For all oral anticoagulants, the pharmacodynamic (PD) marker generally used for individual monitoring is the Prothrombin Time ratio (PTr)….
Read morePopulation Pharmacokinetics of Oral Busulfan in Children
Thursday 16 October, 2025
High-dose busulfan is an important part of many conditioning regimens before autologous or allogeneic bone marrow transplantation in adults and…
Read moreZero-order infusion model for mixed-effects modeling function – NLME
Thursday 16 October, 2025
Nonlinear Mixed-Effects Methods for S-PLUS (mixed-effects modeling function – version 3.3 NLME) have been reported. A zero-order infusion model was…
Read moreFactors Influencing The Choice Of Individualised Dosing Strategies Based On Plasma Concentration, Therapeutic Effect Or Utility
Thursday 16 October, 2025
IntroductionIndividualised dosing may be based on a covariate, on plasma concentration measurements, on the therapeutic effect or on the weighted…
Read morePopulation Modelling Of Type 2 Diabetes Mellitus Disease Progression And Treatment With Pioglitazone (Actos)
Thursday 16 October, 2025
Pioglitazone (Actos) is a novel drug for treatment of Non-Insulin Dependent (type 2) Diabetes Mellitus (NIDDM). Its efficacy has been…
Read more